EP3668853
NÝSTÁRLEG EFNASAMBÖND
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
15.8.2018EP published:
29.9.2021EP application number:
18752172.9
EP translation filed:
2.12.2021Grant published:
15.1.2022EPO information:
European Patent Register
Max expiry date:
14.8.2038Expiry date:
14.8.2026Next due date:
31.8.2026
Title:
NOVEL COMPOUNDS
Timeline
Today
15.8.2018EP application
29.9.2021EP Publication
2.12.2021Translation submitted
15.1.2022Registration published
14.8.2026Expires
Owner
Name:
GlaxoSmithKline Intellectual Property Development LimitedAddress:
GSK Medicines Research Centre, Gunnels Wood Road, Stevenage SG1 2NY, GB
Name:
Bioversys AGAddress:
Technologiepark Basel Hochbergerstrasse 60c, 4057 Basel, CH
Inventor
Name:
PORRAS DE FRANCISCO, EstherAddress:
28760 Madrid, ES
Name:
REMUIÑAN-BLANCO, Modesto JesúsAddress:
28760 Madrid, ES
Name:
BOUROTTE, MarilyneAddress:
59840 Perenchies, FR
Name:
DEPREZ, BenoitAddress:
59000 Lille, FR
Name:
WILLAND, NicolasAddress:
59000 Lille, FR
Priority
Number:
17382570Date:
16.8.2017Country:
EP
Classification
Categories:
C07D 401/04, A61K 31/4427, A61K 31/4523, A61K 31/497, A61K 31/501, A61K 31/506, A61P 31/06
Annual fees
Number
Paid
Expires
Payer
Number: 5
Paid: 20.7.2022
Expires: 14.8.2023
Payer: Patice ehf.
Number: 6
Paid: 20.7.2023
Expires: 14.8.2024
Payer: Árnason Faktor ehf.
Number: 7
Paid: 23.7.2024
Expires: 14.8.2025
Payer: Árnason Faktor ehf.
Number: 8
Paid: 11.8.2025
Expires: 14.8.2026
Payer: Árnason Faktor ehf.